We have three topics for you today: We talk about our recent paper on the use of second-line immunotherapy in kidney cancer, the controversy over whether a cancer clinical trial was unethical, and the results of the randomized clinical trial CASSIOPEIA. 

Kidney Cancer: doi.org/10.1001/jamanetworkopen.2021.24728
CASSIOPEIA doi.org/10.1016/S1470-2045(21)00428-9

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.27 Economics and Medicine with the Host of Freakonomics, M.D., Dr. Anupam Bapu Jena

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com